Literature DB >> 27318995

A long-surviving case of gastric cancer with main portal vein tumor thrombus after surgical resection and postoperative S-1 therapy.

Shinsuke Sato1, Erina Nagai2, Yusuke Taki2, Masaya Watanabe2, Michiro Takahashi2, Yusuke Kyoden2, Ko Ohata2, Hideyuki Kanemoto2, Noriyuki Oba2, Keisei Taku3, Makoto Suzuki4, Masakazu Takagi2.   

Abstract

Gastric cancer patients with main portal vein tumor thrombus usually have a short survival time, owing to its aggressive behavior. Herein, we report a long-surviving case of gastric cancer with main portal vein tumor thrombus. A 78-year-old man presenting with anorexia and body weight loss was diagnosed with gastric cancer. The patient was referred to our hospital for further examination and treatment. Endoscopy revealed a type 3 tumor (8.0 cm in length) in the body of the stomach. Biopsy led to the diagnosis of moderately differentiated adenocarcinoma. Enhanced computed tomography revealed a large tumor thrombus extending from the gastric coronary vein to the portal trunk. A total gastrectomy with lymphadenectomy, splenectomy, and thrombectomy was performed. Postoperative chemotherapy with S-1 was administered for 18 months. The patient died a natural death without recurrence at 49 postoperative months. To the best of our knowledge, the patient was the oldest to be diagnosed with gastric cancer with main portal vein tumor thrombus at diagnosis, who survived >36 months. Although gastric cancer with main portal vein tumor thrombus is a rare occurrence, its prognosis is extremely poor. Intensive surgery and long-term chemotherapy may be effective at improving survival time in these patients.

Entities:  

Keywords:  Chemotherapy; Gastric cancer; Portal vein tumor thrombus; Survival

Mesh:

Substances:

Year:  2016        PMID: 27318995     DOI: 10.1007/s12328-016-0665-4

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  10 in total

1.  Successful treatment of advanced gastric adenocarcinoma with portal tumor thrombosis by total gastrectomy following CDDP and S-1 therapy.

Authors:  Sumiya Ishigami; Takaaki Arigami; Keishi Okubo; Ken Sasaki; Hiroshi Kurahara; Yoshikazu Uenosono; Hiroshi Okumura; Tetsuhiro Owaki; Yuko Kijima; Shinichi Ueno; Shoji Natsugoe
Journal:  Clin J Gastroenterol       Date:  2012-05-19

Review 2.  Portal tumor thrombi due to gastric cancer.

Authors:  Y Sugawara; T Konishi; M Hiraishi; Y Ishizaki; M Makuuchi
Journal:  Hepatogastroenterology       Date:  1996 Jul-Aug

3.  [Resection of a synchronous liver metastasis from gastric cancer associated with portal vein tumor thrombosis - a case report].

Authors:  Hironobu Makino; Hisashi Kametaka; Kazuhiro Seike; Takashi Koyama
Journal:  Gan To Kagaku Ryoho       Date:  2013-11

4.  Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.

Authors:  Toru Aoyama; Takaki Yoshikawa; Takafumi Watanabe; Tsutomu Hayashi; Takashi Ogata; Haruhiko Cho; Akira Tsuburaya
Journal:  Gastric Cancer       Date:  2011-06-30       Impact factor: 7.370

5.  Tumor thrombi in the portal vein system originating from gastrointestinal tract cancer.

Authors:  Akira Tanaka; Ryoji Takeda; Sumio Mukaihara; Katsumi Hayakawa; Koushou Takasu; Hiroaki Terajima; Yoshio Yamaoka; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

6.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

7.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

8.  Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.

Authors:  Wasaburo Koizumi; Toshikazu Akiya; Atsushi Sato; Toshikazu Sakuyama; Eisaku Sasaki; Takashi Tomidokoro; Tsutomu Hamada; Mototsugu Fujimori; Yoshinori Kikuchi; Ken Shimada; Tetsuya Mine; Kensei Yamaguchi; Tsuneo Sasaki; Minoru Kurihara
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-30       Impact factor: 3.333

9.  Long-term survival after sequential chemotherapy and surgery for advanced gastric cancer.

Authors:  Takashi Orii; Yukihiko Karasawa; Hiroe Kitahara; Masaki Yoshimura; Motohiro Okumura
Journal:  Int J Surg Case Rep       Date:  2013-08-15

10.  Salvage surgery after chemotherapy with S-1 plus cisplatin for α-fetoprotein-producing gastric cancer with a portal vein tumor thrombus: a case report.

Authors:  Shigetomi Nakao; Bunzo Nakata; Masashige Tendo; Kenji Kuroda; Takeshi Hori; Mayumi Inaba; Kosei Hirakawa; Tetsuro Ishikawa
Journal:  BMC Surg       Date:  2015-01-16       Impact factor: 2.102

  10 in total
  2 in total

1.  Isolated Superior Mesenteric Vein Tumor Thrombus in a Patient with Gastric Cancer.

Authors:  Barış Özcan; Metin Çevener; Ayşegül Kargı; Mustafa Özdoğan; Alihan Gürkan
Journal:  Case Rep Surg       Date:  2018-03-27

2.  Robotic total gastrectomy with thrombectomy and portal vein reconstruction for gastric cancer and portal vein tumor thrombus.

Authors:  Masaaki Yamamoto; Takeshi Omori; Naoki Shinno; Hisashi Hara; Yosuke Mukai; Takahito Sugase; Tomohira Takeoka; Kei Asukai; Takashi Kanemura; Nozomu Nakai; Shinichiro Hasegawa; Keijiro Sugimura; Hirofumi Akita; Naotsugu Haraguchi; Junichi Nishimura; Hiroshi Wada; Hidenori Takahashi; Chu Matsuda; Masayoshi Yasui; Hiroshi Miyata; Masayuki Ohue
Journal:  World J Surg Oncol       Date:  2022-02-16       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.